siponimod

Pushing hard for blockbuster returns, Novartis finds PhIII data to assert Mayzent boosts cognitive powers in MS patients
Endpoints
Thu, 05/9/19 - 10:43 am
Novartis
Mayzent
siponimod
multiple sclerosis
FDA Raises Concerns With Novartis in Clinical Inspection
RAPS.org
Mon, 05/6/19 - 07:30 pm
Novartis
FDA
Mayzent
siponimod
clinical trials
multiple sclerosis
FDA approves Novartis' Mayzent for MS
BioCentury
Tue, 03/26/19 - 11:02 pm
FDA
Novartis
Mayzent
siponimod
relapsing multiple sclerosis
Roche and Novartis Strengthen Their Presence in the MS Market
BioSpace
Thu, 10/11/18 - 09:35 am
Genentech
Roche
Ocrevus
Novartis
siponimod
FDA
MS
multiple sclerosis
Novartis bets PRV on its next big multiple sclerosis drug — eyes US, EU approvals in ’19
Endpoints
Mon, 10/8/18 - 10:45 am
Novartis
siponimod
MS
multiple sclerosis
Europe
Novartis pads case for new MS blockbuster with disease-progression analysis
Fierce Pharma
Sat, 04/21/18 - 12:41 pm
Novartis
MS
multiple sclerois
siponimod
Novartis' Siponimod significantly improved outcomes in PhIII data published in Lancet
CP Wire
Fri, 03/23/18 - 12:55 am
Novartis
siponimod
clinical trials
MS
multiple sclerosis
SPMS
Novartis' Multiple Sclerosis Life Cycle Looks More Assured
Seeking Alpha
Tue, 09/20/16 - 09:48 am
Novartis
siponimod
MS
multiple sclerosis
Novartis shows a hole card in a high-stakes PhIII poker game for MS drugs
Endpoints
Sat, 09/17/16 - 01:23 pm
Novartis
MS
multiple sclerosis
siponimod